IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#1620
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$2.3B
Richard Adcock
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The company also develops therapeutic agents, which are in Phase II or III clinical trial for the treatment of liquid and solid tumors, including bladder, pancreatic, and lung cancers.
Headcount
590
HQ Base
SAN DIEGO, California
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$IBRX ImmunityBio, Inc. | 52 | 35 | 41 | 89 | - | - | 30.9% | -72.3% | 99.5% | -536.9% | -687.4% | 2962.2% | 0.0% | - | $2.3B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
ImmunityBio, Inc. (IBRX) receives a "Hold" rating with a composite score of 52.4/100. It ranks #1620 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
Outperforming peers — winners tend to keep winning over 3-12 months
Fair valuation relative to peers
Weak fundamentals — higher risk of value trap
High volatility — wider range of outcomes increases timing risk
Aggressive spending — empire-building risk, dilutive growth
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for IBRX.
View All RatingsROIC -5.8% vs WACC 9.0% (spread -14.8%)
GM 100% vs sector 44%, OM -537% vs sector 3%
Capital turnover 0.04x
Rev growth 2962%, 10yr history
Interest coverage -3.6x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate ImmunityBio, Inc. (IBRX) as a Hold with a composite score of 52.4/100 at a current price of $11.57. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
ImmunityBio, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 52.4/100 places it at rank #1620 in our full universe.
The near-term outlook is constructive, with revenue growing at 2962% and momentum in the 89th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
High
Poor
Fair Value
Gross margins of 100% signal strong pricing power.
Returns on equity of 30.9% exceed cost of capital.
Positive momentum indicates institutional accumulation.
Below-average quality raises earnings sustainability concerns.
Vulnerability to macroeconomic shocks and interest rate volatility.
ImmunityBio, Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns ImmunityBio, Inc. a Hold rating, with a composite score of 52.4/100 and 3 out of 5 stars. Ranked #1620 of 7,333 stocks, IBRX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
IBRX's quality score of 35/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of 30.9% (sector avg: -1.9%), gross margins of 99.5% (sector avg: 44.1%), net margins of -687.4% (sector avg: 1.0%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 41/100, IBRX appears somewhat expensive relative to its fundamentals. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
ImmunityBio, Inc.'s investment score of 22/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 2962.2% vs. a sector average of 6.7% and a return on assets of -72.3% (sector: 0.9%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
IBRX shows strong momentum characteristics with a score of 89/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 2962.2% year-over-year, while a beta of 1.48 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
IBRX's stability score of 25/100 signals elevated volatility and/or leverage concerns. Key stability metrics include a beta of 1.48. Investors should be prepared for wider-than-average price swings and consider position sizing accordingly to manage portfolio risk.
The short interest score of 57/100 for IBRX suggests somewhat elevated bearish positioning by institutional traders. Specific risk factors include above-average market sensitivity (beta: 1.48). With a $2.3B market cap (mid-cap), ImmunityBio, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
ImmunityBio, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #1620 of 7,333 overall (78th percentile). Key comparisons include ROE of 30.9% exceeding the -1.9% sector median and operating margins of -536.9% below the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While IBRX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Momentum (89) vs Investment (22) — closing this gap could shift the rating.
ROE 1724% BELOW SECTOR MEDIAN
Gross Margin 126% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 21491% BELOW SECTOR MEDIAN
ImmunityBio Inc. (NASDAQ: IBRX) shares surged following the announcement of a remarkable 700% year-over-year revenue increase, propelled by strong sales of its bladder cancer drug, Anktiva. The company's fourth-quarter revenue significantly beat analyst expectations, and positive technical indicators alongside strategic initiatives contributed to the stock nearing its 52-week high.
ImmunityBio announced significant financial and operational results for 2025, including a 700% year-over-year revenue growth for its ANKTIVA product, reaching $113 million. The company also secured global regulatory approvals for ANKTIVA in bladder cancer across 33 countries and received its first approval for lung cancer in Saudi Arabia, with plans for further label expansion and global commercial partnerships. ImmunityBio emphasizes ANKTIVA's role as a backbone in its Cancer BioShield platform, supported by ongoing clinical trials and long-term patent protection.
ImmunityBio, Inc., an immunotherapy company, achieved significant financial growth in 2025 with $113 million in net product revenue, a 700% year-over-year increase, and a 750% rise in unit sales, despite reporting a net loss of $351.4 million. The company expanded ANKTIVA® approvals globally, formed strategic partnerships, and is advancing its 3-year global strategy including clinical trials and engaging with the U.S. FDA for regulatory pathways. ImmunityBio plans further global expansion and clinical trial enrollments to support sustained commercial growth.
ImmunityBio Inc (NASDAQ: IBRX) is exhibiting a strong long-term uptrend, marked by a confirmed Golden Cross and trading roughly 170% above its 200-day moving average. The stock is also positioned above its 20-day and 50-day moving averages, reinforcing its sustained price strength across various timeframes. Elevated momentum indicators, including an RSI of 67, further support the positive outlook, suggesting continued buying pressure.
ImmunityBio Inc. (NASDAQ: IBRX) saw its stock surge by 8.35% due to promising clinical trial results for non-small cell lung cancer, bladder cancer, and Waldenstrom Lymphoma, alongside key regulatory approvals. The company reported a significant 700% year-over-year sales increase, reaching $113M, and secured accelerated FDA approval in Saudi Arabia for ANKTIVA, bolstering its global expansion strategy. Investors are closely watching its strategic advancements and financial performance as it continues to penetrate new markets and deliver positive clinical outcomes.
Above 50MA
37.18%
Net New Highs
+51081